Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Nelfinavir mesylate and bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Bortezomib may also stop the growth of
hematologic cancer by blocking blood flow to the cancer. Giving nelfinavir mesylate together
with bortezomib may kill more cancer cells.
PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir mesylate
when given together with bortezomib in treating patients with relapsed or progressive
advanced hematologic cancer.